News
from the fight to #SaveIndiePharmacy
New York Times’ The Middlemen series
Medicaid Cuts Are Coming: And Schools Will Pay the Price
When we think about Medicaid, we typically think about health insurance. But Medicaid is also among the largest funding sources for K–12 public schools, providing an estimated $7.5 billion annually to pay for essential services for student learning and development.
Pharmacy Benefit Manager Reform Keeps Getting Scuttled, Despite Bipartisan Support
Despite bipartisan support, a last-ditch effort to pass a healthcare package that included pharmacy benefit manager reforms was scuttled last week. This marks the umpteenth time that lawmakers couldn’t cross the threshold to pass and enact changes to how PBMs do business.
Medicare Drug Coverage Is Often Inadequate—Here’s Why
American healthcare spending dwarfs that of every other wealthy country, and the cost of Medicare, alone, threatens the fiscal viability of the federal government. If insurers do not try to hold down the cost of American medical care, who will?
How Medicare Says It Arrives At ‘Fair’ Prescription Drug Prices
When former President Biden signed the Inflation Reduction Act into law in 2022, he said that drug price negotiations and other provisions in the legislation would help lower costs for Medicare beneficiaries by bringing down the prices of certain medicines and capping out-of-pocket costs for many others. What remained hidden from view, however, is how the so-called maximum fair prices of the drugs selected for negotiation are determined. Now we have a glimpse behind the curtain. But it is only a peek.
Drugmakers including Purdue Pharma paid pharmacy benefit managers not to restrict painkiller prescriptions, a New York Times investigation found.